These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 19149502)

  • 41. The obesity epidemic: current and future pharmacological treatments.
    Hofbauer KG; Nicholson JR; Boss O
    Annu Rev Pharmacol Toxicol; 2007; 47():565-92. PubMed ID: 17002599
    [TBL] [Abstract][Full Text] [Related]  

  • 42. NPY5R antagonism does not augment the weight loss efficacy of orlistat or sibutramine.
    Erondu N; Addy C; Lu K; Mallick M; Musser B; Gantz I; Proietto J; Astrup A; Toubro S; Rissannen AM; Tonstad S; Haynes WG; Gottesdiener KM; Kaufman KD; Amatruda JM; Heymsfield SB
    Obesity (Silver Spring); 2007 Aug; 15(8):2027-42. PubMed ID: 17712121
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Long-term effects of weight-reducing drugs in hypertensive patients--a survey of a Cochrane review].
    Madsbad S
    Ugeskr Laeger; 2011 Feb; 173(8):564-7. PubMed ID: 21333255
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Rimonabant: a novel selective cannabinoid-1 receptor antagonist for treatment of obesity.
    Patel PN; Pathak R
    Am J Health Syst Pharm; 2007 Mar; 64(5):481-9. PubMed ID: 17322160
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Drug treatment of obesity].
    Burniat W
    Rev Med Brux; 2009; 30(2):124-6. PubMed ID: 19517912
    [No Abstract]   [Full Text] [Related]  

  • 46. [The pharmacological treatment of obesity: past, present and future].
    Simonyi G; Pados G; Medvegy M; Bedros JR
    Orv Hetil; 2012 Mar; 153(10):363-73. PubMed ID: 22370224
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Rimonabant improves obesity but not the overall cardiovascular risk and quality of life; results from CARDIO-REDUSE (CArdiometabolic Risk reDuctIOn by Rimonabant: the Effectiveness in Daily practice and its USE).
    Boesten JE; Kaper J; Stoffers HE; Kroon AA; van Schayck OC
    Fam Pract; 2012 Oct; 29(5):521-7. PubMed ID: 22389428
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Orlistat: current status in clinical therapeutics.
    McClendon KS; Riche DM; Uwaifo GI
    Expert Opin Drug Saf; 2009 Nov; 8(6):727-44. PubMed ID: 19998527
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Strategies to reduce vascular risk associated with obesity.
    Bodary PF; Iglay HB; Eitzman DT
    Curr Vasc Pharmacol; 2007 Oct; 5(4):249-58. PubMed ID: 17979791
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Weight management for type 2 diabetes mellitus: global cardiovascular risk reduction.
    Lee M; Aronne LJ
    Am J Cardiol; 2007 Feb; 99(4A):68B-79B. PubMed ID: 17307059
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Efficacy and safety of the weight-loss drug rimonabant.
    Blüher M
    Lancet; 2008 Feb; 371(9612):555-6; author reply 556-7. PubMed ID: 18280321
    [No Abstract]   [Full Text] [Related]  

  • 52. Experimental drugs take aim at obesity.
    Vastag B
    JAMA; 2003 Apr; 289(14):1763-4. PubMed ID: 12684341
    [No Abstract]   [Full Text] [Related]  

  • 53. Comparison of metabolic effects of orlistat and sibutramine treatment in Type 2 diabetic obese patients.
    Derosa G; Cicero AF; Murdolo G; Ciccarelli L; Fogari R
    Diabetes Nutr Metab; 2004 Aug; 17(4):222-9. PubMed ID: 15575343
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Pharmacotherapy of obesity.
    Hofbauer KG; Nicholson JR
    Exp Clin Endocrinol Diabetes; 2006 Oct; 114(9):475-84. PubMed ID: 17115344
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Depression and weight loss: opposite outcome for surgery and rimonabant?
    Chaput JP; Tremblay A
    Obes Rev; 2008 Sep; 9(5):504-7. PubMed ID: 18643944
    [No Abstract]   [Full Text] [Related]  

  • 56. Long-term changes in blood pressure following orlistat and sibutramine treatment: a meta-analysis.
    Johansson K; Sundström J; Neovius K; Rössner S; Neovius M
    Obes Rev; 2010 Nov; 11(11):777-91. PubMed ID: 20025693
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Drug treatment of the overweight patient.
    Bray GA; Ryan DH
    Gastroenterology; 2007 May; 132(6):2239-52. PubMed ID: 17498515
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Obesity: a review of pathogenesis and management strategies.
    Kaila B; Raman M
    Can J Gastroenterol; 2008 Jan; 22(1):61-8. PubMed ID: 18209783
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The new role of pharmacotherapy for weight reduction in obesity.
    Fernstrom MH; Fernstrom JD
    Int J Clin Pract; 2002 Nov; 56(9):683-6. PubMed ID: 12469983
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [No progress without the physician in therapy of obesity].
    Schmidt H; Plauth M
    MMW Fortschr Med; 2000 Jan; 142(4):35-6. PubMed ID: 10850095
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.